

# Infrastrukturen in Zentren und Netzwerken

**Jürgen Lohmeyer**

University of Giessen Lung Center  
Department of Pulmonary & Critical Care Medicine  
Section of Infectious Diseases


**TMF Workshop 27./28. Juni 2011 in Berlin**

# NGFN (1, 2) und NGFN Nachfolgeprogramme (NGFN<sup>plus</sup> und NGFN<sup>transfer</sup>)

- Infektions- und Entzündungsnetz  
(Koord. T. Chakraborty)
- NGFN1: Giessen Research Center in  
Infectious Diseases (GRID):  
Functional Genomics of Bacterium-  
Host Interaction in Sepsis and Septic  
Organ Failure
- NGFN-2:Signatures-Pathways-Genes  
(SIPAGE)




# Nachhaltige Forschungsperspektive




# Pathogenomik der Erreger-Wirt-Interaktion bei entzündlichen Lungenerkrankungen




Trinad Chakraborty/Jürgen Lohmeyer




## Bakterien, bakterielle Produkte, Viren




# Metagenomische Untersuchungen auf Mikroorganismen I



# Metagenomische Untersuchungen auf Mikroorganismen II



Terminale Restriktionslängen-polymorphismus-Analyse von 16S rRNA-Genamplifikaten aus BAL-Proben von 5 Patienten mit COPD.




Zusammensetzung einer 16S rRNA-Gen-Klonbibliothek einer BAL-Probe

Bals, Vogelmeier; unveröffentlichte Daten




# Klinische Forschergruppe Infektiologie




# Standortflora der Lunge und des Respirationstraktes

- Die Standortflora ist notwendig für die Homöostase der Lunge
- Veränderungen in mikrobiellen Gemeinschaften (Mikrobiomen) können zu Erkrankungen (z. B. Morbus Crohn, Colitis ulcerosa, Hauterkrankungen) führen
- Spielt die Standortflora eine Rolle bei entzündlichen und infektiösen Lungenerkrankungen (Pneumonie, Asthma, COPD)?
- 



# UGMLC: Universities Giessen & Marburg Lung Center



# Founding upon a Preexistent “Research Triangle”





## Clinical Research GI

### Internal Medicine

- Pneumology
- Intensive Care Medicine
- Oncology
- Infectious Diseases
- Environmental Medicine

### Thoracic Surgery

### Microbiology

### Virology

### Immunology

### Specialized Professorships

- Lung Fibrosis
- Pulmonary Vascular Research

## Basic Science

### Max-Planck Institute for Heart and Lung Research (B N)

- Lung Development & Remodeling
- Cardiac Development & Remodeling
- Pharmacology

### Basic Science Institutes

- Biochemistry (GI)
- Anatomy (GI, MR)
- Pharmacology (GI, MR)
- Pharmacy (MR)
- Molecular Biology & Tumor Research (IMT, MR)

### Specialized Professorships

- Emphysema, Hypoxia & Lung Aging (GI)
- Lung Matrix Remodeling (GI)
- Molecular Oncology of Lung Cancer (GI)
- Pulmonary Pharmacotherapy (GI)
- Pulmonary Regeneration (GI)
- Radiobiology (MR)

## Clinical Research MR

### Internal Medicine

- Pneumology
- Intensive Care Medicine
- Oncology

### Pediatrics

### Clinical Chemistry and Molecular Diagnostics

### Microbiology

### Virology

### Immunology

### Medical Biometry and Epidemiology

### Coordinating Centre for Clinical Trials (KKS)

### Specialized Professorship

- Bronchopulmonary Remodeling

## Organogenesis

- development
- regeneration

- Stem/progenitor cells
- Signaling in morphogenesis
- Role in pathological remodeling
- Exploitation for reverse-remodeling and regeneration

## Inflammation

- infectious
- non-infectious

- Initiation, spatial control and termination of inflammatory sequelae
- Harnessing for anti-inflammatory therapy and tissue repair

## Hyperproliferation


- (malignant)
- 'benign'

- Control of pulmonary cellularity and matrix homeostasis
- Dissection of cellular and molecular players driving hyperproliferation
- Identification of targets for innovative therapies

**UGMLC Research Focus**

# German Centre for Lung Research

Deutsches Zentrum für Lungenforschung - DZL




# Mission Statement of the DZL

*Translational Research*

*to Combat Widespread*

*Lung Diseases*



# Platforms of the DZL

- Biobanking
- Imaging
- Clinical Trial Board
- DZL School – Joint Educational Programme
- Exploitation
- Lung Information Service

# Biobanking

- Implementation of a DZL biobanking portal
  - Connected to „Technology and Methods Platform for Network Research in Medicine“ (TMF e.V.) and „Biobanking and Biomolecular Resources Research Infrastructure,, (BBMRI) catalogues
  - Comprehensive overview on existing biomaterials, kind and storage location and contact address, consent level, existing ethics votes and phenotyping data
- Harmonisation of operating procedures and policies
  - Informed consent, procurement, collection, labelling, registration, processing, storage, tracking, retrieval, transfer, use and destruction
- Harmonisation of phenotyping tools
  - Central, non-disease related module plus disease-specific extension modules
  - Link to or integration of radiographic and digitalized pathological data


# Imaging: Radiology + Microscopy

- To ensure quality, comparability and translation of results between partner sites as well as preclinical, translational and clinical studies and trials
- Guidance and coordination of projects involving imaging
- Stratification of multiplex, whole range of resolution imaging to serve novel endpoints
- Central administration, standardization, policies and QM
  - Comprehensive ethical and legal framework
  - Implementation of rules for good scientific practice
- Core to share, offer and disseminate imaging technology
- Training in imaging as part of the DZL School

# Clinical Trial Board

- Excellence-based selection process for co-funding of clinical trials starting in 2013
- Investigators submit trial synopsis to the Clinical Trial Board
  - Study protocol and rational, risk-benefit evaluation, statistical analysis plan and power calculation, information on additional funding, advice from competent authorities, IP and feasibility assessment
- Best applications will be presented to the Management Board, which decides on funding
- Innovative Phase I/Illa clinical trials (e.g. GATA-3 specific DNAzyme)
- Well characterized subgroups combined with predictive diagnostic markers (e.g. oncology)
- Studies which explore new indications of already authorized or off-patent medicinal products (e.g. sildenafil)

# Interdependencies





Proposal for the German Centre for Infection Research (DZI)

# HEAL-EMERGE

Hessian Alliance of Excellence in Emerging and Emergency Infections


Coordinator:

Prof. Dr. Trinad Chakraborty  
Centre for Medical Microbiology and Virology  
Justus-Liebig University Giessen  
Frankfurter Str. 107  
35392 Giessen, Germany  
Tel: +49 641 99-41250  
Fax: +49 641 99-41259  
Email: [trinad.chakraborty@mikrobio.med.uni-giessen.de](mailto:trinad.chakraborty@mikrobio.med.uni-giessen.de)


Vice-Coordinator:

Prof. Dr. Stephan Becker  
Institute of Virology  
Philipps-University Marburg  
Hans-Meerwein-Str. 2  
35043 Marburg, Germany  
Tel: +49 6421 28-66253  
Fax: +49 6421 28-68962  
Email: [becker@staff.uni-marburg.de](mailto:becker@staff.uni-marburg.de)

  
Prof. Dr. Joybrato Mukherjee  
President  
Justus-Liebig University Giessen

  
Prof. Dr. Katharina Krause  
President  
Philipps-University Marburg

  
Prof. Dr. Günther Grabatin  
President  
University of Applied Sciences  
Giessen-Friedberg

  
Prof. Dr. Klaus Cichutek  
President  
Paul-Ehrlich Institute  
Langen



Hessian Alliance of Excellence in Emerging and Emergency Infections

Justus-Liebig University Giessen, Philipps-University Marburg, University of Applied Sciences Giessen-Friedberg, Paul-Ehrlich-Institute Langen

Basic Research	Clinical Research	Associated Centres
<p><b>Faculty of Medicine</b> Biochemistry (GI) Anatomy and Cell Biology (GI) Pharmacology (GI, MR) Immunology (MR) Neuroanatomy (MR)</p> <p><b>Faculty of Veterinary Medicine</b> Virology (GI) Microbiology &amp; Hygiene (GI) Clinic for Birds, Animals &amp; Reptiles (GI) Parasitology (GI) Pathology (GI)</p> <p><b>Faculty of Agriculture &amp; Nutrition &amp; Environmental Management</b> Biochemistry (GI) Phytopathology and Appl. Zoology (GI)</p> <p><b>Faculties of Biology &amp; Chemistry</b> Biochemistry (GI) Microbiology (MR) Inorganic &amp; Analyt. Chemistry (GI, MR)</p> <p><b>Fraunhofer Research Group</b> on Insect Biotechnology (GI)</p> <p><b>Faculty of Pharmacy</b> Pharmaceutical Technology &amp; Biopharmacy (MR) Pharmaceutical Chemistry (MR)</p> <p><b>Faculty of Mathematics</b> Computational Intelligence &amp; Bioinformatics (MR)</p> <p><b>University of Applied Sciences</b> Institute of Biopharmaceutical Technology Institute of Biochemical Engineering and Analytics</p> <p><b>Paul-Ehrlich-Institut</b></p>	<p><b>Faculty of Medicine Institutes</b> Microbiology (GI, MR) Virology (GI, MR) Clinical Immunology (GI) Hygiene (GI, MR) Clinical Chemistry (MR)</p> <p><b>Clinical Departments</b> Urology (GI) Anaesthesiology (GI, MR) Trauma Surgery (GI) Ear-Nose-Throat (GI, MR) Dermatology (MR) Internal Medicine • Infectious Diseases (GI, MR) • Gastroenterology (GI, MR) • Endocrinology (GI, MR) Paediatrics (GI, MR) • Paediatric Pulmonology and Allergy (GI) • Neuropaediatrics (GI) School of Dentistry • Periodontology (GI) • Paediatric Dentistry (GI)</p> <p><b>Specialized Professorships</b> Molecular Vaccinology (GI, MR) Human Microbial Ecology (GI) Vaccine Immunology (MR)</p>	<p>LOEWE Centre Synmikro (MR) MPI for Terrestrial Microbiol. (MR) LOEWE Centre UGMLC (GI, MR) LOEWE-MIBIE (GI, MR, FH) LOEWE-Ambiprobe (GI, FFM) LOEWE-Insect Biotechnology (GI, FH, FFM, MR) LOEWE-Tumour &amp; Inflammation (MR, GI) LOEWE-Bioengineering &amp; Imaging (FH, MR) LOEWE-Changes in Virus Pathogenicity (MR) Coordinating Centre for Clinical Trials (KKS, MR) Coordinating Centre for Pediatric Clinical Trials (KKFP, MR)</p> <p>University Hospital Giessen &amp; Marburg GmbH</p> <p>TransMIT GmbH</p> <p><b>Industrial Partners</b> • DRG Instruments GmbH (MR) • Intervet International BV • Novartis V&amp;D (MR)</p>

Fig. 1 – HEAL-EMERGE – Participating institutions

Management  
Board

DZI

International Scientific  
Advisory Board

# HEAL-EMERGE

Hessian Alliance of Excellence in Emerging and Emergency Infections

Justus-Liebig University Giessen, Philipps-University Marburg,  
University of Applied Sciences Giessen-Friedberg, Paul-Ehrlich-Institute Langen

**Coordinator: T. Chakraborty, JLU Giessen**

Vice Coordinator: S. Becker, PU Marburg  
Central Management

**Steering Committee (preliminary)**

JLU Giessen: K. Becker; PU Marburg: M. Lohoff; Univ. of Applied Sciences: P. Czermak;  
Paul-Ehrlich-Institute: K. Cichutek; Junior Res. Group: N.N.

**Rapid Detection**

Organizers:  
E. Hüllermeier/H.-J. Thiel

**Vaccines**

Organizers:  
M. Lohoff/J. Ziebuhr

**Novel antiinfectives**

Organizers:  
K. Becker/G. Klebe

**Techn. Platforms**

Organizers:  
B. Spengler/R. König

**Scientific Faculty**



UH  
Universität Hamburg  
DIE FORSCHUNG | DER LEHR | DAS BEGRIFFEN



Universitätsklinikum  
Hamburg-Eppendorf



UNIVERSITÄT ZU LÜBECK



HPI  
Heinrich Heine Institute  
Leibniz Institute für Experimentelle Virologie



Forschungszentrum  
**Borstel**



Wissenschaftliche  
Friedrich-Wilhelms-  
Universität Bonn



Universität zu Köln



DEUTSCHES  
KREBSFORSCHUNGZENTRUM  
IN DEN HELMOLZ-INSTITUTEN

**dkfz.**

FRIEDRICH-WILHELM  
UNIVERSITÄT  
TÜBINGEN



MAX-PLANCK-INSTITUT  
FOR ENTWICKLINGSBIOLOGIE



German Cancer Research  
Center  
**UKT**  
University of Tuebingen



TECHNISCHE  
UNIVERSITÄT  
MÜNCHEN



LMU  
LUDWIG-MAXIMILIANS-  
UNIVERSITÄT MÜNCHEN  
HelmholtzZentrum münchen  
Deutsches Forschungszentrum für Gesundheit und Umwelt



MHH  
Medizinische Hochschule  
Hannover



Stiftung Tierärztliche  
Hochschule Hannover



TWINCORE  
Zentrum für  
Krebsforschung  
und Klinische Onkologie



HEMHOLTZ  
ZENTRUM FÜR  
INFektionsforschung



Technische  
Universität  
Braunschweig



DSMZ  
Deutsche  
Sammlung von  
Mikroorganismen  
und Zelllinien GmbH

JUSTUS-LIEBIG-  
UNIVERSITÄT  
GIESSEN



Philipps  
Universität  
Marburg



Paul-Ehrlich-Institut



FACHHOCHSCHULE  
**GIESSEN**  
FRIEDBERG



Bundeswehr

Fig. 1 - Map of Germany with DZIF partner sites and institutions




Fig.2 - Inner core of DZIF, associated institutions and collaborating German Research Centres

# DZIF

Deutsches Zentrum für Infektionsforschung

Infectious disease  
research areas

1. Hepatitis	2. Staphylococcal infections	3. Bacterial infections of the gastro-intestinal tract	4. Infections of the immuno-compromised host	5. HIV/AIDS	6. Malaria	7. Tuberculosis	8. Emerging infections	9. Infections caused by resistant Gram-negative bacteria
--------------	------------------------------	--	--	-------------	------------	-----------------	------------------------	--

Cross sectional  
research areas

10. Immune control and immunisation

11. Anti-Infectives

Infrastructure


12. Scientific infrastructure


13. Clinical infrastructure

14. Education and training

# DZL: Added Value through Integrated Approach

- **Common Mission Statement**  
*Translational research to combat widespread lung diseases*
- **Complementary Disease Focus**  
Airway - Lung Parenchyma - Vasculature  
Paediatric - Adult
- **Complementary Expertise**  
Basic Science - Disease-orientated - Patient-orientated – Epidemiological Research
- **Complementary Institutional Background**  
Helmholtz - Max Planck - Leibniz – Fraunhofer - University Hospitals – Pneumology Centres
- **Bundling of Resources**  
Knowledge - Technologies - Biobanks - Patient cohorts
- **Synergies in Technologies**  
Molecular Tools - Animal Models - Imaging & Biobank - Clinical Trials & Epidemiology
- **Synergies in Budgetary Focus**  
Investment in shared technologies - Coherent development strategy
- **Incentives for Cooperation**  
Largely cooperative disease programmes - Clinical trial funds – Exchange programmes





# Goals

**Access to sufficient numbers of high quality samples and associated high quality data has already become the most obstructive bottleneck of medical research**

**The establishment of integrated nationwide research centers such as DZI/DZL might be one of the few possibilities to efficiently advance harmonization of existing biobanks**

**The establishment of the intended and internationally leading biobank platform is seen as one of the major structural outcomes of DZI/DZL**

**Implementation of a DZL-internet portal with connection to BBMRI catalogues and the German Biobankregister**

**Development of SOPs and policies**

**Harmonisation of phenotyping tools finally on an integrated IT infrastructure**

**Include a biobank for material from preclinical models**



Bundesministerium  
für Bildung  
und Forschung



**Infektiologie/  
Immunologie**



**Infektiologie/  
Immunologie**





## Biomedizinisches Zentrum Seltersberg (BFS)



# Zusammenfassung

- Lokal sind an vielen Standorten e-Infrastrukturen etabliert, die lokal gepflegt und fortentwickelt werden müssen (Biobanken, Patientenkohorten, KKS etc.)
- Für die Vernetzung in den Deutschen Zentren der Gesundheitsforschung ist eine Harmonisierung dieser Infrastrukturen über eine zentrale IT-Plattform erforderlich